Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2014-12-18 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science EN
Regulatory Filings Classification · 95% confidence The document is a press release dated December 18, 2014, announcing 'Positive Clinical Study Data' regarding the follow-up of a Phase 2 trial for the drug Masitinib in metastatic colorectal cancer. It details efficacy endpoints (OS, PFS, ORR), compares results to benchmarks, describes the ongoing Phase 3 study, and provides background on the drug and the company. This content structure—announcing specific clinical trial results and updates on development status—is characteristic of an Earnings Release (ER) or a general announcement related to scientific/clinical progress, which often accompanies or precedes formal financial reporting. Since it is focused purely on clinical trial results and development pipeline updates rather than comprehensive financial performance for a period (like 10-K or IR), and it is an announcement of data rather than a transcript or presentation, the most fitting category is Earnings Release (ER), as clinical updates are frequently bundled with earnings announcements, or it could be considered a Regulatory Filing (RNS) if no earnings context is present. Given the detailed nature of the results announcement, ER is a strong candidate, but since it is not explicitly an 'Earnings Release' header and focuses heavily on scientific data, it fits best as a general announcement of material information. However, in the context of financial reporting categories, announcements of key clinical milestones are often classified under ER if they are material news releases. Since the document is a press release detailing positive clinical data, it functions as a material announcement. If a specific 'Clinical Trial Update' category existed, that would be ideal. Lacking that, and noting it is a formal announcement of results, ER is the closest fit for material news dissemination, though RNS is a possibility if it's purely regulatory/non-financial news. Given the context of financial reporting databases, material news like this is often grouped with ERs. I will classify it as ER based on the nature of the announcement being material news dissemination, similar to how preliminary results are often released.
2014-12-18 English
AB Science FR
Investor Presentation Classification · 95% confidence The document is titled "Compte rendu de la conférence web sur le masitinib dans l'asthme" (Summary of the web conference on masitinib in asthma) and provides an update on clinical trial progress (Phase 3 futility test passed, IDMC recommendation to continue) and future development plans (launching new Phase 3 and Phase 2 studies). This content is highly specific to ongoing research, clinical data review, and strategic pipeline updates, which aligns best with an Investor Presentation (IP) or a detailed Management Discussion/Report summary, rather than a formal regulatory filing like 10-K or ER. Since it summarizes a specific event (a web conference) detailing clinical and strategic progress, Investor Presentation (IP) is the most appropriate classification, as it serves to inform investors about key operational and R&D milestones.
2014-12-02 French
AB Science EN
Call Transcript Classification · 98% confidence The document is titled "Masitinib in Asthma – Summary of Web Conference" and explicitly states that it provides a "summary of the key points of the web conference held on 2nd December 2014". This content is a transcript or summary derived directly from a conference call where company updates (clinical trial progress, expansion plans) were discussed. This fits the definition of a Call Transcript (CT), which covers full text transcripts of company conference calls, including earnings calls.
2014-12-02 English
AB Science EN
Regulatory Filings Classification · 85% confidence The document is a press release dated November 28, 2014, announcing a specific operational update: the advancement of a novel drug candidate (AB8779) into full preclinical development for treating B-cell malignancies and inflammatory diseases. This type of announcement, detailing research progress, drug pipeline updates, and scientific findings, is characteristic of corporate communications in the pharmaceutical sector. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a transcript (CT). Since it details a specific development milestone and is presented as a news announcement, it best fits the general category for corporate news that isn't strictly financial reporting or management changes. Given the options, it is a specific corporate update. While it could potentially be classified as 'Regulatory Filings' (RNS) as a catch-all, the content is highly specific to R&D progress. However, none of the provided codes explicitly cover 'R&D Pipeline Update' or 'Press Release'. In the context of financial filings, announcements about drug development milestones are often released via general regulatory channels. Since it is a specific announcement about a product/research advancement and not a standard financial report, and given the available codes, 'Regulatory Filings' (RNS) serves as the most appropriate general category for non-standard, material corporate announcements that don't fit the other specific financial/governance codes.
2014-11-28 English
AB Science FR
Regulatory Filings Classification · 95% confidence The document is a press release dated November 28, 2014, announcing that AB Science is launching a new SYK kinase inhibitor (AB8779) into regulatory preclinical development. It details the scientific rationale, preclinical *in vitro* and *in vivo* data, and includes quotes from management. This type of announcement, focusing on R&D progress, drug pipeline updates, and scientific milestones, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a formal announcement detailing scientific progress and strategy rather than a mandatory regulatory filing (like 10-K or MRQ) or a simple earnings release (ER), 'Investor Presentation' (IP) is the most fitting category for detailed pipeline updates, although it is structured as a press release. Given the options, 'IP' covers detailed scientific/pipeline updates best. It is not a formal regulatory filing like 10-K, nor is it a transcript (CT) or a management discussion (MDA) of past results. It is a forward-looking announcement about a drug candidate's progress.
2014-11-28 French
AB Science EN
Call Transcript Classification · 85% confidence The document is an announcement dated November 25, 2014, detailing an upcoming 'Web conference' scheduled for December 2, 2014, regarding the drug Masitinib in asthma treatment. It outlines the topics, participating key opinion leaders, and mentions that the supporting presentation will be made available *after* the call. This structure—announcing a specific event (a conference call with Q&A) where experts discuss clinical data—is characteristic of a company hosting a call to discuss results or updates, which aligns best with the definition of a Call Transcript (CT), even though this document is the *announcement* of the call, not the transcript itself. However, since the document is an announcement about a specific event that will generate discussion/Q&A, and it is not a formal regulatory filing (like 10-K or ER), it is most closely related to the content discussed in a Call Transcript. Given the options, and recognizing this is an announcement for a specific informational event, it is not a standard ER (which is usually the initial financial results release) or IP (which is usually a broader investor deck). Since the event is a 'web conference' with Q&A, it strongly implies a discussion format similar to an earnings call. If the document were only announcing the *release* of a report, RPA would be appropriate. Here, the announcement is for a live discussion/presentation event. In the absence of a specific 'Event Announcement' code, and given the nature of the content (clinical update discussion), CT is the closest fit for the *type* of information being conveyed, although RPA might be argued if we strictly follow the 'Menu vs Meal' rule for announcements. Given the detailed agenda and expert lineup, it's an announcement for a specific informational session, which often precedes a CT. I will classify this as a Call Transcript (CT) as it describes the content and format of a scheduled call discussion, which is the primary purpose of the communication, rather than just announcing a report publication.
2014-11-25 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.